| Laryngocarcinoma is a common malignant tumor in head had neck. The surgeryof the disease will damage the throat and damage the quality of our life. And thesensitivity of laryngeal cancer cells is different with each other to radiotherapy, soradiotherapy is not a therapy good enough. Glioma is a common intracranialmalignant tumor. Because of its invision and has no obvious difference with braintissue，it is difficult to remove by surgery. Radiotherapy is harmful to the function ofbrain. Melanoma is a malignant tumor of melanocytes, most early patients can becured with surgery, but advanced patients’ lifetime is short, and their survival rate islow. In addition melanoma is not sensitive to radiation treatment, malignantmelanoma is regarded as a antiradiation malignant cancer. From what has beendiscussed above, drug therapy has become a very important solution to cure GliomaLaryngocarcinoma and Melanoma. However chemotherapy’s treatment effect islimited, and there are some serious toxic side effects. It can’t improve the patients’survival rates significantly. So it is necessary to develop a new drug which is efficientand low-toxic for the treatment of glioma and laryngocarcinoma.Ganoderma lucidum is a medical fungus, has been used in traditional Chinesemedicine for thousand years. Ganoderma lucidum has been reported to containimmunomodulating and antitumor agents. Ganoderma lucidum immunoregulatoryprotein (LZ-8) is fungal immunomodulatory proteins which is extracted from the redganoderma lucidum mycelium. The medicine which is used in this paper isRecombinant Ganoderma lucidum immunoregulatory protein （rLZ-8），and thesamples were resigned and coded according to LZ-8genes which gained from Pichiapastoris. According to the research before, rLZ-8has some antitumor activities. Forexample, rLZ-8has significant lethal effect in promyelocytic leukemic cell line NB4,human lung cancer cell line A549, human gastric carcinoma cell line SGC7901and soon. But there is no report about the therapeutic effect of rLZ-8to glioma and larygocarcinoma.The study of pharmacodynamics is divided into two parts: in vitro and in vivoexperiment. We use different concentrations of rLZ-8to test its killing effect of Hep-2,C6and A549by MTT method. The results display that rLZ-8could kill Hep-2, C6and A549cell in vitro. The killing effect of rLZ-8to Hep-2and A549is in time-dosedependent. The killing effect of rLZ-8to C6cells is in a dose-dependent manner. Alsowe treated Hep-2, C6and A549cells with rLZ-8and evaluated cell apoptosis usingflow cytometry. The result showed that rLZ-8produced little efficacy in apoptosisinduction to Hep-2, however rLZ-8can produced significant efficacy in apoptosisinduction to C6cells and the efficacy is in a dose-dependent manner. At same times,rLZ-8also has a little efficacy in apoptosis induction to C6cells.In vivo experiment using subcutaneous inoculation Hep-2, C6and A549to nudemouse to establish Laryngeal, glioma and melanoma mouse model. Inoculation cellnumber are5×106. We measure weight of nude every day during the delivery, alsomeasure volume twice a week, and also record Nude mice tumor size along with thechange of delivery time of each group. After one day of inoculation，we begin the tailvein to medicine. The experimental results show that rLZ-8can reduce the tumorvolume and tumor weight of the laryngeal transplantation tumor in nude mice. But theresults have no significant difference when compared to model group. rLZ-8hasobvious therapeutic effect for glioma. It can significantly inhibit the tumorigenesis,and the tumor volume and tumor weight of the glioma which is treated by rLZ-8havesignificant difference when compared to model group(P＜0.01). Only high-doserLZ-8has obvious therapeutic effect for glioma. We also do HE staining on thestripped tumor tissue. The results show that rLZ-8can cause a wide range of necrosisin tumor tissue, and the necrosis of glioma tissue is more obvious. The results aboveshow that rLZ-8has tumor suppression effect to larygocarcinoma, and has obvioustreatment effect to glioma and melanoma. |
PDF Full Text Request